---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-23-000018"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:11:50.886840+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics reports Q4 net loss $21.1M; cash $122.8M; BDTX-1535 update H2 2023

## Summary
- Net loss $21.1M in Q4 2022, full year net loss $91.2M (vs $125.6M in 2021).
- Cash, cash equivalents and investments $122.8M as of Dec 31, 2022; sufficient into Q3 2024.
- Phase 1 update for EGFR inhibitor BDTX-1535 expected H2 2023; trial actively recruiting.
- FDA cleared IND for BRAF/RAS inhibitor BDTX-4933; Phase 1 start expected H1 2023.
- Spinout of Launchpad Therapeutics with $30M Series A led by Versant and NEA; BDTX retains minority stake.

## SEC filing metadata
- accession: 0001701541-23-000018
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/0001701541-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/bdtx-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-23-000018
- JSON: https://secwatch.observer/filing/0001701541-23-000018.json
- Plain text: https://secwatch.observer/filing/0001701541-23-000018.txt

## Key facts
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 9, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/0001701541-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.